Wave Life Sciences Inc.

Last updated September 27, 2026

Organization details

Legal name
Wave Life Sciences Inc.
Ownership
Public
Status
Active
Headquarters country
Singapore
Ticker symbol
WVE
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001631574

Board of directors

Chief executives

Paul Bolno · President and CEO
Dates unknown

Board connections

4 of this board's directors also sit on 26 other boards.

Network of Wave Life Sciences Inc.'s board connections ARS Pharmaceuticals Inc. ARS Pharmaceuticals In... Acrivon Therapeutics Inc. Acrivon Therapeutics I... Acumen Pharmaceuticals Inc. Acumen Pharmaceuticals... Artiva Biotherapeutics Inc. Artiva Biotherapeutics... Bicara Therapeutics Inc. Bicara Therapeutics In... Black Diamond Therapeutics Inc. Black Diamond Therapeu... Climb Bio Inc. Climb Bio Inc. Evommune Inc. Evommune Inc. Freenome Inc. Freenome Inc. Hemab Therapeutics Holdings Inc. Hemab Therapeutics Hol... Jade Biosciences Inc. Jade Biosciences Inc. Janux Therapeutics Inc. Janux Therapeutics Inc... LENZ Therapeutics Inc. LENZ Therapeutics Inc. Mineralys Therapeutics Inc. Mineralys Therapeutics... Nkarta Inc. Nkarta Inc. Parabilis Medicines Inc. Parabilis Medicines In... Peter Kolchinsky Peter Kolchinsky Rajeev M. Shah Rajeev M. Shah Wave Life Sciences Inc.
Shared director Other board Same sector +10 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$82,561,068
6 purchases by 2 insiders
Sold, last 12 months
$16,182,860
47 sales by 11 insiders
Date Insider Transaction Shares Price Value
Aug 12, 2026 Adrian Rawcliffe Director Open-market sale −12,700 $5.29 $67,183
Aug 11, 2026 Ken Takanashi Director Open-market sale −3,864 $6.01 $23,223
Aug 11, 2026 Aik Na Tan Director Open-market sale −432 $6.01 $2,596
Aug 11, 2026 Heidi L. Wagner Director Option exercise +7,000 $5.97 $41,790
Aug 11, 2026 Heidi L. Wagner Director Open-market sale −7,000 $6.01 $42,070
Mar 30, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner Open-market purchase +971,091 $6.50 $6,312,092
Mar 27, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner Open-market purchase +2,495,623 $6.43 $16,046,856
Mar 26, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner Open-market purchase +4,954,558 $6.06 $30,024,621
Mar 26, 2026 RA CAPITAL MANAGEMENT, L.P. Director, 10% owner Open-market purchase +351,224 $6.38 $2,240,809
Mar 23, 2026 Ken Takanashi Director Derivative conversion +3,901,348 — —
Feb 26, 2026 Francis Chris Officer (See Remarks) Option exercise +17,900 $3.87 $69,273
Feb 26, 2026 Francis Chris Officer (See Remarks) Open-market sale −17,900 $15.09 $270,111
Feb 26, 2026 Francis Chris Officer (See Remarks) Option exercise +15,294 $4.75 $72,647
Feb 26, 2026 Francis Chris Officer (See Remarks) Open-market sale −15,294 $15.00 $229,410
Feb 9, 2026 Moran Kyle Officer (Chief Financial Officer) Open-market sale −3,588 $13.45 $48,259

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.